Valneva Reports Impressive 2024 Financial Performance
Valneva SE, a specialty vaccine company, announced its preliminary unaudited financial results for 2024, showcasing remarkable growth in both sales revenue and total revenues. With a notable increase of 10% in total revenues, reaching €169.6 million compared to the previous year’s €153.7 million, Valneva is clearly moving in the right direction. This growth is even more pronounced in product sales, which surged by 13%, reaching €163.3 million from €144.6 million in 2023.
Robust Cash Position at Year-End
As of December 31, 2024, Valneva boasts a strong cash position of €168.3 million. This figure represents a significant increase from €126.1 million at the end of 2023. This boost can be attributed to strategic moves, including the successful sale of a Priority Review Voucher and a private placement that raised €60 million, providing Valneva with greater financial flexibility.
Looking Forward: 2025 Financial Outlook
As Valneva moves into 2025, it anticipates further growth with sales revenues projected to increase to between €170-180 million. Total revenues are expected to reach between €180-190 million, reflecting the company’s positive trajectory. The company also plans to invest between €90-100 million in research and development, partially offset by anticipated grant funding and R&D tax credits.
Strategic Investments and Lower Operating Costs
An important focus for 2025 will be maintaining a stringent cash management strategy, which is anticipated to substantially reduce operating cash burn to under €30 million compared to over €60 million in the previous year. This will enable Valneva to strategically invest in its R&D efforts while ensuring financial stability.
Clinical and Regulatory Achievements
In 2024, Valneva made substantial headway in its clinical and regulatory efforts. The company continued to advance its Lyme disease vaccine program, successfully completed primary vaccinations in a Phase 3 study, and reported additional positive Phase 2 booster results. This kind of progress is vital as it lays the groundwork for future advancements in the vaccine pipeline.
Regulatory Approvals and Strategic Partnerships
Valneva secured regulatory approvals for its chikungunya vaccine, IXCHIQ®, across multiple regions, including Canada and Europe. Furthermore, the company received a significant grant of $41.3 million from the Coalition for Epidemic Preparedness Innovations (CEPI) to enhance access to its groundbreaking chikungunya vaccine. These achievements underscore Valneva's commitment to addressing unmet medical needs globally.
Upcoming Catalysts to Watch
Looking ahead, Valneva is poised for several significant milestones in 2025. The anticipated Phase 3 results for the Lyme disease vaccine candidate, VLA15, are expected by year-end. Additional approvals for IXCHIQ®, including pediatric trials, will further extend the vaccine’s coverage and market reach. The company is also advancing its Shigella vaccine candidate through to Phase 2b trials, which could lead to important future developments.
About Valneva SE
Valneva SE is dedicated to developing, manufacturing, and commercializing innovative vaccines. The company's specialized approach focuses on addressing significant infectious disease threats. With a portfolio that includes the world's first chikungunya vaccine and ongoing efforts to advance vaccines against Lyme disease, Zika virus, and Shigella, Valneva's commercial success is vital for supporting the further development of its pipeline.
Valneva Investor and Media Contacts
Laetitia Bachelot-Fontaine
VP, Global Communications and European Investor Relations
M +33 (0)6 4516 7099
investors@valneva.com
Joshua Drumm, Ph.D.
VP, Global Investor Relations
M +001 917 815 4520
joshua.drumm@valneva.com
Frequently Asked Questions
What was Valneva's revenue in 2024?
Valneva reported total revenues of €169.6 million for the year 2024.
How much cash did Valneva have at the end of 2024?
Valneva reported a cash position of €168.3 million at year-end 2024.
What is Valneva's outlook for revenue growth in 2025?
The company expects sales revenues to grow to between €170-180 million in 2025.
What significant regulatory achievements did Valneva have in 2024?
Valneva secured regulatory approvals for its chikungunya vaccine and made progress in its Lyme disease vaccine program.
What are some upcoming developments to watch for in 2025?
Notable upcoming milestones include Phase 3 results for the Lyme disease vaccine and expanded approvals for IXCHIQ®.
